BIEIOTCinactive

PREMIER BIOMEDICAL INC

Healthcare·Oncology·Commercial·Jackson Center, PA, United States
OncologyNeurologyImmunologyOphthalmologyInfectious DiseasePain

PREMIER BIOMEDICAL INC (BIEI): 3 pipeline candidates · 1 clinical trial. Updated within the last hour.

8.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.06 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for PREMIER BIOMEDICAL INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.7M

Cash

—

Quarterly Burn

$71K

Runway

—

Revenue

$1K

Pipeline (3 candidates)

DrugPhase
feldetrexPreclinical
sequential-dialysis techniquePreclinical
softactApproved
1 clinical trial·CEO: William Hartman

Frequently asked questions

How many drug candidates are in PREMIER BIOMEDICAL INC's pipeline?

PREMIER BIOMEDICAL INC (BIEI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is PREMIER BIOMEDICAL INC's lead drug candidate?

PREMIER BIOMEDICAL INC's most advanced tracked candidate is feldetrex (Preclinical) for Multiple sclerosis, fibromyalgia, neuropathic pain and traumatic brain injury.

What is PREMIER BIOMEDICAL INC's market capitalization?

PREMIER BIOMEDICAL INC's market capitalization is approximately $1.7M.

Who is the CEO of PREMIER BIOMEDICAL INC?

William Hartman is the chief executive officer of PREMIER BIOMEDICAL INC (BIEI).

Get the full picture on PREMIER BIOMEDICAL INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar